US 12,435,074 B2
Physics-driven discovery of novel small therapeutic compounds for use as a BCL-2 inhibitor
Muge Didem Orhan, Besiktas/Istanbul (TR); Serdar Durdagi, Besiktas/Istanbul (TR); Berna Dogan, Besiktas/Istanbul (TR); Seyma Calis, Besiktas/Istanbul (TR); Gurbet Cacan, Besiktas/Istanbul (TR); and Timucin Avsar, Besiktas/Istanbul (TR)
Assigned to BAHCESEHIR UNIVERSITESI, Istanbul (TR)
Appl. No. 17/929,003
Filed by BAHCESEHIR UNIVERSITESI, Besiktas/Istanbul (TR)
PCT Filed Feb. 10, 2021, PCT No. PCT/TR2021/050122
§ 371(c)(1), (2) Date Aug. 10, 2022,
PCT Pub. No. WO2021/162668, PCT Pub. Date Aug. 19, 2021.
Claims priority of application No. 2020/02072 (TR), filed on Feb. 11, 2020.
Prior Publication US 2023/0099876 A1, Mar. 30, 2023
Int. Cl. C07D 409/14 (2006.01); A61K 31/4709 (2006.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01)
CPC C07D 409/14 (2013.01) [A61K 31/4709 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01)] 15 Claims
OG exemplary drawing
 
1. A compound according to formula I, or a pharmaceutically acceptable derivative thereof,

OG Complex Work Unit Chemistry
wherein the pharmaceutically acceptable derivative of Formula I is a hydrate, a solvate, a stereoisomer, a salt, an ester, a tautomer, or an isotopically labeled derivative thereof.